Pellino 3 promotes the colitis-associated colorectal cancer through suppression of IRF4-mediated negative regulation of TLR4 signalling
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young-Mi | - |
dc.contributor.author | Kim, Hye-Youn | - |
dc.contributor.author | Ha Thi, Huyen Trang | - |
dc.contributor.author | Kim, Jooyoung | - |
dc.contributor.author | Lee, Young Jae | - |
dc.contributor.author | Kim, Seong-Jin | - |
dc.contributor.author | Hong, Suntaek | - |
dc.date.accessioned | 2024-01-16T12:30:48Z | - |
dc.date.available | 2024-01-16T12:30:48Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 1574-7891 | - |
dc.identifier.issn | 1878-0261 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90098 | - |
dc.description.abstract | The incidence of colitis-associated colorectal cancer (CAC) has increased due to a high-nutrient diet, increased environmental stimuli and inherited gene mutations. To adequately treat CAC, drugs should be developed by identifying novel therapeutic targets. E3 ubiquitin-protein ligase pellino homolog 3 (pellino 3; Peli3) is a RING-type E3 ubiquitin ligase involved in inflammatory signalling; however, its role in the development and progression of CAC has not been elucidated. In this study, we studied Peli3-deficient mice in an azoxymethane/dextran sulphate sodium-induced CAC model. We observed that Peli3 promotes colorectal carcinogenesis with increased tumour burden and oncogenic signalling pathways. Ablation of Peli3 reduced inflammatory signalling activation at the early stage of carcinogenesis. Mechanistic studies indicate that Peli3 enhances toll-like receptor 4 (TLR4)-mediated inflammation through ubiquitination-dependent degradation of interferon regulatory factor 4, a negative regulator of TLR4 in macrophages. Our study suggests an important molecular link between Peli3 and colonic inflammation-mediated carcinogenesis. Furthermore, Peli3 can be a therapeutic target in the prevention and treatment of CAC. | - |
dc.format.extent | 16 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Pellino 3 promotes the colitis-associated colorectal cancer through suppression of IRF4-mediated negative regulation of TLR4 signalling | - |
dc.type | Article | - |
dc.identifier.wosid | 001020458100001 | - |
dc.identifier.doi | 10.1002/1878-0261.13475 | - |
dc.identifier.bibliographicCitation | MOLECULAR ONCOLOGY, v.17, no.11, pp 2380 - 2395 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85162932904 | - |
dc.citation.endPage | 2395 | - |
dc.citation.startPage | 2380 | - |
dc.citation.title | MOLECULAR ONCOLOGY | - |
dc.citation.volume | 17 | - |
dc.citation.number | 11 | - |
dc.type.docType | Article | - |
dc.publisher.location | United States | - |
dc.subject.keywordAuthor | colitis-associated colorectal cancer | - |
dc.subject.keywordAuthor | IRF4 | - |
dc.subject.keywordAuthor | Pellino 3 | - |
dc.subject.keywordAuthor | TLR4 | - |
dc.subject.keywordPlus | TOLL-LIKE RECEPTORS | - |
dc.subject.keywordPlus | ABERRANT CRYPT FOCI | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | COLON INFLAMMATION | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | IRF4 | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.